Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and.

Slides:

Advertisements

Similar presentations

ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified

Advertisements

Combination Antiretroviral Therapy for HIV Infection by Ormrat Kampeerawipakorn.

ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

HIV-1 dynamics Perelson et.al. Science 271:1582 (1996) Infected CD4 + lymphocytes Uninfected, activated CD4 + lymphocytes HIV-1 t 1/ days t 1/2.

Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.

Why African Americans Must Understand and Participate in Clinical Trials and Vaccines Virginia A. Caine, M.D. Associate Professor of Medicine Division.

Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.

 The Life Cycle of HIV  Step 1: Binding and Fusion  Drugs which affect this: › Fusion inhibitors › CCR5 Inhibitors

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Antiretroviral Therapy (ART)

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

AIDS Chien-Ming Li MD, Ph.D.

ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort.

Laboratory diagnosis and biosafety issues of biological warfare agents

Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial

Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected.

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine TOTEM

Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses

Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract A. Torres-Cornejo, O.J.

Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive.

HIV Prevention and Treatment: The Evolving Role of the Emergency Department Kristi Stanley, MD, Meredith Lora, MD, Stephen Merjavy, MD, Jennifer Chang,

M. Colafigli, C. Torti, E. M. Trecarichi, L. Albini, A. Rosi, V

Salvage therapy for multidrug-resistant tuberculosis

Approach to diagnosis of infective endocarditis

Herpes zoster in non-hospitalized children

Analysis of transmitted drug resistance in Spain in the years 2007–2010 documents a decline in mutations to the non-nucleoside drug class S. Monge, V.

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV

Drug-resistant human immunodefiency virus

Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure

Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.

Analysis of intracellular human immunodeficiency virus (HIV)-1 drug resistance mutations in multi-failed HIV-1-infected patients treated with a salvage.

Vector control: a cornerstone in the malaria elimination campaign

Systematic review or meta-analysis

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

New HCV therapies on the horizon

G. Höffken Clinical Microbiology and Infection

Volume 4, Issue 10, Pages e433-e441 (October 2017)

Forecasting for ARVs medicines

Laboratory diagnosis and biosafety issues of biological warfare agents

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Salvage therapy for multidrug-resistant tuberculosis

V Duque, ÁA. Holguín, M. Silvestre, J. GonzÁAlez-Lahoz, V. Soriano

G. Rocheleau, C.J. Brumme, J. Shoveller, V.D. Lima, P.R. Harrigan

F. Canducci, B. Barda, E. Ceresola, V. Spagnuolo, M. Sampaolo, E

Levofloxacin in the treatment of ventilator-associated pneumonia

Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007–2009 S. Di Giambenedetto, M. Prosperi, I.

T.M. File Clinical Microbiology and Infection

Sexually acquired Zika virus: a systematic review

Antiretroviral therapy and its complications

C. Tamalet, P. Colson, E. Decroly, C. Dhiver, I. Ravaux, A. Stein, D

Volume 377, Issue 9777, Pages (May 2011)

F. Ceccherini-Silberstein, V. Cento, V. Calvez, C.-F. Perno

Statin use and clinical outcomes among pneumonia patients

W. Eugene Sanders, Christine C. Sanders

AZT = Azidothymidine (3’-azido-3’-deoxythymidine, Zidovudine)

Virology: a scientific discipline facing new challenges

O. Megged, A.M. Yinnon, D. Raveh, B. Rudensky, Y. Schlesinger

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy M. Franzetti, M.

Figure 1. Rate of PDR in infants according to ARV exposure

The future of diagnostic bacteriology

ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE

Presentation transcript:

Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and 400 systematic reviews and meta-analyses S. Kanters, E.J. Mills, K. Thorlund, H.C. Bucher, J.P.A. Ioannidis Clinical Microbiology and Infection Volume 20, Issue 2, Pages 114-122 (February 2014) DOI: 10.1111/1469-0691.12475 Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 The number of randomized clinical trial (RCT) and systematic review/meta-analysis publications pertaining to antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) treatment-naïve adults. We searched ten electronic databases (MEDLINE via PubMed, Cochrane CENTRAL, EMBASE, CINAHL, AMED, PsychINFO, Clincaltrials.gov, HIV drug resistance database, Global Health, and Web of Science) for randomized trials of individual ART by using the search terms ‘MESH agents, antiretroviral’, ‘MESH HIV’, ‘MESH Acquired immunodeficiency syndrome’, ‘random*’, and ‘naïve or initial or early’. We searched for systematic reviews by using the same search terms with the addition of ‘systematic review OR meta-analysis’, and used the Pubmed Clinical Query search filter for systematic reviews. Clinical Microbiology and Infection 2014 20, 114-122DOI: (10.1111/1469-0691.12475) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 Network of viral suppression comparisons for randomized clinical trials (RCTs) among treatment-naïve human immunodeficiency virus (HIV)-positive adults. Each treatment is represented by a circle, and lines between the circles represent comparisons that exist in the network of RCTs. (a) Pertains to all regimens according to drug classes. (b) Pertains to all backbone combinations compared within RCTs. Each of these nodes includes a third agent, not shown in the figure. In 75% of cases the agent is efavirenz, but in some cases the agent is a protease inhibitor. ABC, abacavir; AZT, zidovudine; ddI, didanosine; d4T, stavudine; FI and CCR5, fusion inhibitors; FTC, emtricitabine; II, integrase inhibitor; II/c, cobicistat-boosted integrase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted protease inhibitor; 3TC, lamivudine; TDF, tenofovir. Clinical Microbiology and Infection 2014 20, 114-122DOI: (10.1111/1469-0691.12475) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions